Isatuximab in combination with RVd improves MRD negativity
At this year’s ASH annual meeting, latest results from the phase III GMMG-HD7 trial will be presented. The trial indicates that addition of isatuximab to standard of care in patients with newly-diagnosed multiple myeloma significantly decreases detection of myeloma cells.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
